Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Atara Biotherapeutics, Inc.

Advances in™ Transplant: Identifying and Managing EBV-Associated Post-Transplant Lymphoproliferative Disorder

Release Date: June 30, 2021
Expiration Date: June 30, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of posttransplant lymphoproliferative disorders (PTLD), with a forward-looking perspective on how new and novel agents might impact clinical practice. This information is presented in a multimedia format, and includes a series of video interviews with expert thought leaders integrated into text-based elements. The PTLD comprise a broad spectrum of heterogenous lymphoproliferative lesions that arise in immunocompromised individuals after solid organ transplant (SOT) or allogeneic hematopoietic stem cell transplant (ASCT). PTLD is one of the most devastating complications of an organ transplant. The optimal therapy has, until recently, remained elusive. However, immunotherapies may provide an eagerly awaited alternative for the treatment of Epstein-Barr virus (EBV)-positive PTLD in the near future.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Atara Biotherapeutics, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, surgical oncologists, and pathologists who treat patients with EBV+ PTLD. Nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment of disease will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the pathophysiology of EBV-positive PTLD, diagnostic criteria, and current standards of care for this transplant-related complication
  • Review the rationale underlying the development of immunotherapeutic approaches for EBV-positive PTLD
  • Assess the efficacy and safety profiles of immunotherapies evaluated for the treatment of EBV-positive PTLD
  • Evaluate practice-changing clinical data on immunotherapies in the context of evolving treatment algorithms for EBV-positive PTLD

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Birte Wistinghausen, MD
Birte Wistinghausen, MD
Associate Professor of Pediatrics
Division of Oncology
The George Washington University
Medical Unit Director
Center for Cancer and Blood Disorders
Children’s National Hospital
Washington, DC

Disclosures: Birte Wistinghausen has no relevant financial relationships with ineligible companies.

Priya Verghese, MBBS, MPH, FAST
Priya Verghese, MBBS, MPH, FAST
Division Head of Nephrology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures: Priya Verghese has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By